

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1-22. (Canceled)

23. (New) A peptide having SEQ ID NO: 1, wherein the peptide has an amino terminus selected from the group consisting of an NH₂ group and a biotin-aminohexanoyl group.

24. (New) The peptide of claim 23, wherein the amino terminus of SEQ ID NO: 1 is the NH₂ group.

25. (New) The peptide of claim 23, wherein the amino terminus of SEQ ID NO: 1 is the biotin-aminohexanoyl group.

26. (New) A composition comprising the peptide of claim 23 and a pharmaceutically acceptable carrier.

27. (New) The composition comprising the peptide of claim 24 and a pharmaceutically acceptable carrier.

28. (New) The composition of claim 23 wherein the composition is effective for treating or inhibiting a herpes simplex virus infection in a warm-blooded animal.

29. (New) The composition of claim 23 wherein the composition is effective for treating or inhibiting an HSV-1 infection in a warm-blooded animal.

30. (New) The composition of claim 24 wherein the composition is effective for treating or inhibiting a herpes simplex virus infection in a warm-blooded animal.

31. (New) The composition of claim 24 wherein the composition is effective for treating or inhibiting an HSV-1 infection in a warm-blooded animal.

32. (New) A method of treating a virus infection in a warm blooded animal comprising administering an effective amount of the peptide of claim 23 to the animal, wherein the virus is herpes simplex virus.

33. (New) The method of claim 30 wherein the herpes simplex virus is HSV-1.

34. (New) A method of treating a virus infection in a warm blooded animal comprising administering an effective amount of the peptide of claim 24 to the animal, wherein the virus is herpes simplex virus.

35. (New) The method of claim 34 wherein the herpes simplex virus is HSV-1.